CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer’s disease
Lizama BN, Willaims C, North HA, et al. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer’s disease. Alzheimer’s Dement. 2024; 1-21.